Literature DB >> 6114901

Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.

R G Long, J R Peters, S R Bloom, M R Brown, W Vale, J E Rivier, D G Grahame-Smith.   

Abstract

During a control infusion noradrenaline and alcohol each provoked carcinoid flushing in four of five patients and pentagastrin in two of five patients. When tetradecapeptide somatostatin was infused on another day no patient flushed at any time, even when 16 microgram of either noradrenaline or pentagastrin were administered. Carcinoid flushing was not associated with release of gastrin or any of the other vasoactive or postprandially released gut regulatory peptides measured. In a sixth patient with severe prolonged carcinoid flushing, subcutaneous Des AA1, 2, 4, 5, 12D Trp8 somatostatin markedly reduced the incidence and severity of flushing for two days. Somatostatin is thus a potent inhibitor of carcinoid flushing, but no evidence has been found for the gut hormones measured to be mediators of flushing.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114901      PMCID: PMC1419330          DOI: 10.1136/gut.22.7.549

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Current problems in the measurement of gastrin release. A reproducible measure of physiological gastrin release.

Authors:  R C Russel; S R Bloom; L P Fielding; M G Bryant
Journal:  Postgrad Med J       Date:  1976-10       Impact factor: 2.401

2.  Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature.

Authors:  L J Roberts; S R Marney; J A Oates
Journal:  N Engl J Med       Date:  1979-02-01       Impact factor: 91.245

3.  Somatostatin. Total solid phase synthesis.

Authors:  J E Rivier
Journal:  J Am Chem Soc       Date:  1974-05-01       Impact factor: 15.419

4.  A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties.

Authors:  J D Albano; R P Ekins; G Maritz; R C Turner
Journal:  Acta Endocrinol (Copenh)       Date:  1972-07

5.  Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells.

Authors:  J M Polak; A G Pearse; L Grimelius; S R Bloom
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

6.  The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin.

Authors:  J C Frölich; Z T Bloomgarden; J A Oates; J E McGuigan; D Rabinowitz
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

7.  Editorial: Somatostatin: newcomer from the hypothalamus.

Authors:  P Brazeau; R Gullemin
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

8.  Measurement of fasting and postprandial plasma VIP in man.

Authors:  S J Mitchell; S R Bloom
Journal:  Gut       Date:  1978-11       Impact factor: 23.059

9.  Plasma enteroglucagon and plasma volume change after gastric surgery.

Authors:  J P Thomson; S R Bloom
Journal:  Clin Sci Mol Med       Date:  1976-08

10.  Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.

Authors:  M Sheppard; B Shapiro; B Pimstone; S Kronheim; M Berelowitz; M Gregory
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

View more
  10 in total

1.  [2 year interferon therapy of metastatic carcinoid tumor].

Authors:  W von Scheidt; M Böhm; I Huber; R Habersetzer; K Jacob; A Markl; G Autenrieth
Journal:  Klin Wochenschr       Date:  1990-02-15

2.  What is the cause of the carcinoid flush?

Authors:  D G Grahame-Smith
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

3.  Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.

Authors:  B Wiedenmann; U Räth; R Rädsch; F Becker; B Kommerell
Journal:  Klin Wochenschr       Date:  1988-01-15

4.  Gastroenteropancreatic endocrine tumors.

Authors:  C Weil
Journal:  Klin Wochenschr       Date:  1985-05-15

5.  Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.

Authors:  P Ruszniewski; M Ducreux; J A Chayvialle; J Blumberg; D Cloarec; H Michel; J M Raymond; J L Dupas; H Gouerou; R Jian; E Genestin; P Bernades; P Rougier
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

6.  Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue.

Authors:  I Whitehouse; C Beglinger; G Rüttimann; K Gyr
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

7.  Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects.

Authors:  M E Kraenzlin; S M Wood; M Neufeld; T E Adrian; S R Bloom
Journal:  Experientia       Date:  1985-06-15

Review 8.  Use of octreotide acetate for control of symptoms in patients with islet cell tumors.

Authors:  P N Maton
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Somatostatin and the dumping syndrome.

Authors:  R G Long; T E Adrian; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

10.  Medical treatment of gastroenteropancreatic neuroendocrine tumors.

Authors:  Anja Rinke; Patrick Michl; Thomas Gress
Journal:  Cancers (Basel)       Date:  2012-02-08       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.